Defining and Targeting the Oncogenic Drivers of Neuroendocrine Prostate Cancer.

ABSTRACT: In this issue of Cancer Cell, Lee and colleagues (2016) define the biologic role of MYCN in promoting prostate tumorigenesis and development of a neuroendocrine phenotype. This has important implications for the clinical management of neuroendocrine prostate cancer as Aurora A kinase inhibitors promoting N-Myc destabilization progress in the clinic.

SUBMITTER: Carver BS 

PROVIDER: S-EPMC5550814 | biostudies-other | 2016 Apr

REPOSITORIES: biostudies-other